Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Anti-Mullerian Hormone, a Measure of Ovarian Reserve, Is Low in Female Subjects in the Multi-Center Study of Hydroxyurea

Lydia H. Pecker, MD, Eli Salzberg, Shruti Chaturvedi, MBBS, MS, Ni Zhao, MD PhD, Mindy S Christianson, MD MBA, Sophie M. Lanzkron, MD

Blood (2019) 134 (Supplement_1): 890.

https://doi.org/10.1182/blood-2019-122137

Published: 2019

Journal Articles

A Novel Phthalimide-Derivative, TC11, Induced G2/M Arrest and Apoptosis of High-Risk Myeloma Cells By Interacting with Nucleophosmin1 and α-Tubulin, but Not By Binding to Celeblon

Misa Nakamura, Daiju Ichikawa, PhD, Shuji Aida, Nahoko Hashimoto, Wakana Murota, Ryo Uozaki, Mikio Okayama, MD, Kota Fujimori, Yuko Yonemura, Noriko Tabata, PhD, Hiroshi Yanagawa, PhD, Maiko Matsushita, MD PhD, Yutaka Hattori, MD PhD

Blood (2017) 130 (Supplement 1): 5377.

https://doi.org/10.1182/blood.V130.Suppl_1.5377.5377

Published: 2017

Journal Articles

Cereblon and Redox in Plasma Cells

Florian Bassermann, MD PhD

Blood (2017) 130 (Supplement 1): SCI-9.

https://doi.org/10.1182/blood.V130.Suppl_1.SCI-9.SCI-9

Published: 2017

Journal Articles

A Prospective Study of IV Pentamidine for Pneumocystis Jirovecii Pneumonia Prophylaxis in Adult Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplant or Chemotherapy

Jennifer Anderson, PharmD, Scott Wirth, PharmD, Pritesh R. Patel, MD, John G. Quigley, MD, Annie L. Oh, MD, Christina Mactal-Haaf, PharmD, Irum Khan, MD, Damiano Rondelli, MD, Karen Sweiss, PharmD

Blood (2016) 128 (22): 2207.

https://doi.org/10.1182/blood.V128.22.2207.2207

Published: 2016

Journal Articles

Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs

Masashi Hozumi, Daiju Ichikawa, PhD, Maiko Matsushita, MD PhD, Eriko Kamiyama, Hiroshi Yanagawa, PhD, Noriko Tabata, PhD, Shotaro Kitabatake, Arimi Ueda, Takashi Yamaguchi, Mariko Sato, Yutaka Hattori, MD PhD

Blood (2015) 126 (23): 1800.

https://doi.org/10.1182/blood.V126.23.1800.1800

Published: 2015

Journal Articles

Development of a Novel Phthalimide Derivative, Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts

Yutaka Hattori, MD PhD, Maiko Matsushita, MD PhD, Noriko Tabata, Hirokazu Shiheido, Hiroshi Yanagawa, PhD, Arimi Ueda, Masashi Hozumi, Shotaro Kitabatake, Daiju Ichikawa

Blood (2014) 124 (21): 5718.

https://doi.org/10.1182/blood.V124.21.5718.5718

Published: 2014

Journal Articles

The Effect of Nilotinib in Chronic Myeloid Leukemia Treatment Dose on Spermatogenesis and Folliculogenesis in a Healthy Mouse Model

Guldane Seval, MD, Sinan Ozkavukcu, MD, Murat Seval, MD, Meltem Ayli, MD, Muhit Ozcan, MD

Blood (2014) 124 (21): 1799.

https://doi.org/10.1182/blood.V124.21.1799.1799

Published: 2014

Journal Articles

Mechanism of Lenalidomide Activity in Multiple Myeloma

Jan Krönke, MD

Blood (2014) 124 (21): SCI-51.

https://doi.org/10.1182/blood.V124.21.SCI-51.SCI-51

Published: 2014

Journal Articles

Exchange Transfusion In Adult Patients With Sickle Cell Disease With Refractory Vaso-Occlusive Crises

Padmini Moffett, MD, Bryan K Moffett, MD

Blood (2013) 122 (21): 4689.

https://doi.org/10.1182/blood.V122.21.4689.4689

Published: 2013

Journal Articles

High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide

Anna T Jonasova, MD, Jaroslav Polak, Martin Vostry, Arnost Kostecka, Radka Bokorova, Radana Neuwirtova, MD, PhD, Magda Siskova, MD, Miroslav Caniga, Dana Sponerova, Jaroslav Cermak, Dana Mikulenková, MD, Jana Brezinova, PhD, Kyra Michalova, PhD, Ota Fuchs, PhD

Blood (2013) 122 (21): 1529.

https://doi.org/10.1182/blood.V122.21.1529.1529

Published: 2013

Journal Articles

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide

Alexander Klimowicz, PhD, Paola Neri, MD, PhD, Andrew Belch, MD, Michelle Dean, Li Ren, PhD, Kathy Gratton, Jiri Slaby, MD, Jordan Johnson, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCPC, Nizar J. Bahlis, MD

Blood (2012) 120 (21): 931.

https://doi.org/10.1182/blood.V120.21.931.931

Published: 2012

Journal Articles

Induction of CRBN(Cereblon) mRNA Expression by Baicalein

Zi Ma, Sr., Rui bo Zhang, Li He, Chao ping Xu, Ding xin Zhou, Jing na Ji, Jianying Huang, Yicheng Zhang, Sr., Shang qin Liu, Sr.

Blood (2012) 120 (21): 5025.

https://doi.org/10.1182/blood.V120.21.5025.5025

Published: 2012

Journal Articles

Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide

Yuan Xiao Zhu, PhD, Esteban Braggio, PhD, Chang-Xin Shi, PhD, Jessica Schmidt, Laura Bruins, Steven R. Schuster, MD, Rafael Fonseca, MD, P. Leif Bergsagel, MD, Chad C. Bjorklund, Ph.D., Robert Z. Orlowski, MD, PhD, A. Keith Stewart, MD

Blood (2011) 118 (21): 127.

https://doi.org/10.1182/blood.V118.21.127.127

Published: 2011

Journal Articles

High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone

Daniel Heintel, Arnold Bolomsky, Martin Schreder, MD, Sabine Pfeifer, Niklas Zojer, Ulrich Jäger, Heinz Ludwig, MD

Blood (2011) 118 (21): 2879.

https://doi.org/10.1182/blood.V118.21.2879.2879

Published: 2011

Journal Articles

Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease

Suzette O. Oyeku, MD, MPH, Nancy S. Green, MD, Farzana Pashankar, MD, Patricia Giardina, MD, Craig A. Mullen, MD, PhD, Catherine Driscoll, MD

Blood (2010) 116 (21): 255.

https://doi.org/10.1182/blood.V116.21.255.255

Published: 2010

Journal Articles

Hydroxyurea in Children with Sickle Cell Disease: Practice Patterns and Barriers to Utilization.

Amanda M. Brandow, DO, MS, Danielle L. Jirovec, BA, Julie A. Panepinto, MD, MSPH

Blood (2009) 114 (22): 242.

https://doi.org/10.1182/blood.V114.22.242.242

Published: 2009

Journal Articles

Health Status of Offspring Conceived During Hydroxyurea Therapy for Sickle Cell Disease.

Saloni Tanna, MD, Betsy Clair, Sejal Kuthiala, MD, Teresa A. Coleman, MD, FACP, Abdullah Kutlar, MD

Blood (2009) 114 (22): 1533.

https://doi.org/10.1182/blood.V114.22.1533.1533

Published: 2009

Journal Articles

Developmental Outcomes of Offspring of Adults Treated with Hydroxyurea in the Multicenter Study of Hydroxyurea.

F. Daniel Armstrong, Ph.D., Martin H Steinberg, MD, Samir K. Ballas, MD, Kenneth I. Ataga, MD, Myron A Waclawiw, PhD, Abdullah Kutlar, MD, Paul S. Swerdlow, MD, William F. McCarthy, Ph., D., for the MSH Extension Investigators

Blood (2009) 114 (22): 1543.

https://doi.org/10.1182/blood.V114.22.1543.1543

Published: 2009

Journal Articles

Successful Treatment of Acute Myelocytic Leukemia in Pregnancy Complicated with Lung Abscess

Jianping Lan, Xiaogang Wang, Ye Peng, Meihua Qian, Lianmin Wang, He Huang, MD, PhD

Blood (2008) 112 (11): 4019.

https://doi.org/10.1182/blood.V112.11.4019.4019

Published: 2008

Journal Articles

Successful Full-Term Live Birth in an Allogeneic Stem Cell Transplant Patient with Active Extensive Chronic Graft-Versus-Host Disease.

Heather Shah, MD, Donna Salzman, M.D., Khaleel Ashraf, M.D., William Vaughan, M.D.

Blood (2007) 110 (11): 5016.

https://doi.org/10.1182/blood.V110.11.5016.5016

Published: 2007

NARROW

Anti-Mullerian Hormone, a Measure of Ovarian Reserve, Is Low in Female Subjects in the Multi-Center Study of Hydroxyurea

A Novel Phthalimide-Derivative, TC11, Induced G2/M Arrest and Apoptosis of High-Risk Myeloma Cells By Interacting with Nucleophosmin1 and α-Tubulin, but Not By Binding to Celeblon

Cereblon and Redox in Plasma Cells

A Prospective Study of IV Pentamidine for Pneumocystis Jirovecii Pneumonia Prophylaxis in Adult Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplant or Chemotherapy

Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs

Development of a Novel Phthalimide Derivative, Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts

The Effect of Nilotinib in Chronic Myeloid Leukemia Treatment Dose on Spermatogenesis and Folliculogenesis in a Healthy Mouse Model

Mechanism of Lenalidomide Activity in Multiple Myeloma

Exchange Transfusion In Adult Patients With Sickle Cell Disease With Refractory Vaso-Occlusive Crises

High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide

High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide

Induction of CRBN(Cereblon) mRNA Expression by Baicalein

Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide

High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone

Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease

Hydroxyurea in Children with Sickle Cell Disease: Practice Patterns and Barriers to Utilization.

Health Status of Offspring Conceived During Hydroxyurea Therapy for Sickle Cell Disease.

Developmental Outcomes of Offspring of Adults Treated with Hydroxyurea in the Multicenter Study of Hydroxyurea.

Successful Treatment of Acute Myelocytic Leukemia in Pregnancy Complicated with Lung Abscess

Successful Full-Term Live Birth in an Allogeneic Stem Cell Transplant Patient with Active Extensive Chronic Graft-Versus-Host Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only